About Us

Landos Biopharma is a late clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Leveraging our AI-based integrated computational platform, LANCE, we have identified seven novel clinical and preclinical candidates across various areas of unmet medical need. Our lead product candidate, omilancor (BT-11), is a small molecule targeting Lanthionine Synthetase C-Like 2 (LANCL2), a pathway designed to limit its impact to the gastrointestinal tract. In 2021, the Company reported final results from a Phase 2 proof-of-concept trial of omilancor in patients with mild-to-moderate ulcerative colitis (UC) and is preparing to initiate a global pivotal Phase 3 program of omilancor in UC patients. Additionally, Landos initiated a Phase 2 trial of omilancor for the treatment of moderate-to-severe Crohn’s disease (CD) in May 2021.

The Company’s mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm for autoimmune disease.

Management Team

Josep Bassaganya-Riera

Josep Bassaganya-Riera, Ph.D.

Chairman, President and CEO

Read More
Raquel Hontecillas

Raquel Hontecillas, Ph.D.

Chief Scientific Officer

Read More
Jyoti Chauhan

Jyoti Chauhan, M.S., RAC (US)

Executive Vice President, Clinical & Regulatory Affairs

Read More
Andrew Leber

Andrew Leber, Ph.D.

Vice President, Discovery and Product Development

Read More

Marek Ciszewski, J.D.

Vice President, Financial Strategy and Investor Relations

Read More
simon lichtiger

Simon Lichtiger, M.D.

Vice President, Clinical Development and Medical Affairs

Read More

Nuria Tubau-Juni, Ph.D.

Director of Immunology and Inflammation

Read More
Jennifer Collette

Jennifer Collette, CPA

Vice President, Finance and Controller

Read More

Board of Directors

Josep Bassaganya-Riera, Ph.D.

Chairman, President and CEO

Read More

Fred Callori

Xontogeny, Perceptive Advisors

Read More

Chris Garabedian

Xontogeny, Perceptive Advisors

Read More

Tiago Girão

CFO of RoiVant Sciences

Read More

Tim M. Mayleben

Read More

Roderick Wong, M.D., MBA

Managing Partner, RTW Investments

Read More

Clinical Advisory Board

Jean-Frederic Colombel, M.D.

Read More

Maria T. Abreu, M.D.

Read More

Fabio Cominelli, M.D., Ph.D.

Read More

Asher Kornbluth, M.D.

Read More

Francisco Sylvester, M.D.

Read More